Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a private sector company. He also offers his insights into Daewoong Bio’s diversified business model and highlights the need for internationalization.
From a corporate perspective, domestic mid-sized pharmaceutical companies like Daewoong Bio must pursue a diversified portfolio focused on both generic drugs and new innovative products to drive sustainable growth
